Official Title
Adverse Events Related to Treatments Used Against Coronavirus Disease 2019
Brief Summary

The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Iatrogenic Disease
Acute Kidney Injury
ARDS, Human

Drug: Any drug used to treat Covid-19

lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.

Eligibility Criteria

Inclusion Criteria:

- all patients treated for Covid-19

Exclusion Criteria:

- Chronology not compatible between the drug and the toxicity

Eligibility Gender
Eligibility Age
Minimum: N/A ~ Maximum: N/A

AP-HP Assistance Publique Hopitaux de Paris
Paris, France

Joe-Elie Salem, MD, PhD, Study Director
Clinical Investigations Center

CMC Ambroise Paré
NCT Number
MeSH Terms
Coronavirus Infections
Respiratory Distress Syndrome
Acute Kidney Injury
Iatrogenic Disease